Abbott Laboratories is settling the case involving its two units, Arriva Medical LLC and its parent company Alere Inc. The American medical devices and health care company headquartered in Illinois will be paying $160 million to resolve the said units’ kickbacks and false claims cases.
The settlement stemmed from the allegations that Arriva Medical and Alere Inc. submitted untruthful claims to Medicare, a government health plan, by offering kickbacks to diabetes patients. According to the U.S. Department of Justice, some of the things they offered include free glucose monitors.
Reuters reported that the settlement was done on Monday, Aug. 2. This will resolve claims that Arriva Medical and Alere violated the country’s False Claims Act from 2009 to 2016 by transferring Medicare funding from where it was needed.
The U.S. DOJ stated that Arriva gave away glucose monitors at no cost to persuade patients to place orders for more testing supplies. It was added that Arriva also typically waives co-payments. It was further alleged that the company has been systematically charging Medicare for glucose monitors that were handed out to ineligible patients, plus submitting claims for 211 patients who were already dead for at least two weeks.
Gregory Goodman, the whistleblower of the scheme, worked at Arriva call center in Tennessee, and he will be getting $28.5 million from the settlement. Then again, despite the settlement, it was reported that the defendants did not admit liability.
"Doing anything that defrauds the government or the Medicare program, it's fellow Americans who end up paying for it," Goodman said. "The decision to move forward was quite simple."
According to the Tennessean, the now-retired employee knew something was not right when he took a call center job at Arriva almost 10 years ago. Prior to his stint at the medical supply company, he has been an account executive for investment firms.
He had little experience in the healthcare industry, so when he noticed that something was off, he did some research. Goodman explained he thinks the way the firm was driving customer service reps to sell those glucometers and waive co-payments was not normal. With this week’s settlement, it was proven that Abbott’s unit really did something wrong.


Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only
Asian Currencies Hold Steady as Indian Rupee Slides to Record Low on Fed Outlook
Oil Prices Rebound as U.S.-Venezuela Tensions Offset Oversupply Concerns
U.S. Stock Futures Mixed as Tech and AI Stocks Face Pressure Ahead of CPI Data
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO
BOJ Expected to Deliver December Rate Hike as Economists See Borrowing Costs Rising Through 2025
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies
U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound
Asian Currencies Steady as Fed Delivers Hawkish Rate Cut; Aussie and Rupee Under Pressure 



